Revenue

A go-kart empire's philanthropic efforts, fueled by its elderly dog mascot, result in a nearly quarter-million-dollar donation to animal shelters.

Facing huge losses and a China crackdown, crypto miner Intchains bets its future on a new staking platform and accumulating a massive ETH treasury.

Surpassing $2B in sales and achieving sustained profitability, The RealReal's 2025 results signal a new era for the luxury resale giant. But can it last?

With its Healthcare Services platform growing, SelectQuote executives will face investors to detail their tech-driven strategy amid market pressures.

Tectonic Therapeutic reports key clinical progress in two distinct rare diseases, backed by a strong cash position and new leadership for its next phase.

Sysco's latest dividend declaration offers more than shareholder returns; it provides a key signal on the health of the global food service industry.

Oportun celebrates a major financial turnaround and its fifth straight profitable quarter, but a closer look reveals rising delinquencies and new headwinds.

The diagnostics firm topped revenue forecasts with explosive growth in core tests, navigating a net loss with a strategic pivot into new markets.

One in 10 Canadians has kidney disease, often with no symptoms. Experts urge immediate action as this silent crisis strains lives and our healthcare system.

After a $544M annual loss from impairment charges, the performance parts maker is cutting costs and exploring the sale of its Marucci baseball brand.

Sunrun reports a major financial turnaround, pivoting to a storage-first strategy that turns home batteries into a powerful virtual power plant.

The safety solutions leader adds a top CFO and CEO to its board, a strategic move to bolster financial oversight and drive growth amid record performance.

Neurizon Therapeutics has started dosing its promising ALS drug, NUZ-001, in the groundbreaking HEALEY Platform Trial, a pivotal step for patients.

After a strategic pivot to focus purely on cell and gene therapy, BioLife reports strong revenue growth and a profitable quarter, eyeing further gains in 2026.

Facing user burnout and fierce rivals, Tinder's first-ever product event aims to reignite the flame. Can new tech and a new vision save the dating giant?

The AI semiconductor firm posts 37% annual revenue growth and a return to non-GAAP profit, proving its strategic pivot to intelligent edge devices is a success.

Structure Therapeutics reports strong Phase 2 data for its oral obesity pill, aleniglipron, positioning it as a key contender in the race for pill-based GLP-1s.

The 3M spin-off navigates a transformative year, posting strong organic growth driven by MedSurg and Dental, despite a reported sales dip from divestitures.

Skydio's autonomous drones have answered 10 million calls, powered by deep integration that gets eyes on scene in under 60 seconds. But what does this mean?

A new study shows alternating magnetic fields can destroy antibiotic-resistant biofilms on medical implants, offering hope for a non-surgical treatment.